Analyst: New Eli Lilly drug doesn't throw Novo Nordisk's Ozempic curveball
Danish bank analyst Søren Løntoft from Sydbank estimates that Eli Lilly has presented a decent set of data for new drug tirzepatide, but hardly enough to outmatch Novo's Ozempic drug.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
On Wednesday, US pharmaceutical company Eli Lilly presented another batch of decent trial results with the GIP/GLP-1 analog tirzepatide, which is comparable with Novo's semaglutide, marketed as Ozempic and Rybelsus, on several counts.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
